Hematoma Absorption and Neurological Function Recovery
Conditions
Keywords
panax notoginseng saponins, hypertensive intracerebral hemorrhage, hematoma, neurological function
Brief summary
The purpose of this study is to determine whether panax notoginseng saponins are effective in the treatment of Hypertensive Intracerebral Hemorrhage Patients.
Detailed description
Patients with HICH were randomly assigned to receive either PNS integrated with conventional therapy. Patients were treated with conventional therapy for 3 days, then plus PNS for 14 days. Patients in the control group received conventional therapy for 17days. Hematoma volume measured by CT scanning, National Institutes of Health Stroke Scale (NIHSS) scores, Barthel index (BI), all the three were used to evaluate the therapeutic effect for both groups after two weeks of intervention.
Interventions
Panax Notoginseng Saponins integrated with conventional therapy
Sponsors
The First People's Hospital of Jingzhou
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* with a history of hypertension treated with medication and blood pressure management ( a systolic blood-pressure target of 140 to 179 mmHg and a diastolic blood-pressure target of 70 to 100 mmHg) during the period of hospitalization, * the site of hematoma located in one of the cerebral hemispheres, * hematoma volume 10-30ml, * no blood in the ventricles, * within 24 hours of onset of first-time acute intracerebral hemorrhage, * no loss of consciousness (drowsiness acceptable).
Exclusion criteria
* cerebellar or brainstem hemorrhage, * intracerebral hemorrhage caused by bleeding diathesis, aneurysms, vascular malformations, improperly using anticoagulant drugs, or suspicious amyloid angiopathy, * subarachnoid hemorrhage; multifocal hemorrhage, * mixed stroke or hemorrhagic infarct, * coexisting systematic diseases such as heart or kidney failure, tumors, gastrointestinal hemorrhage and so on, * pregnant or lactating women, * a history of XUESAITONG injection anaphylaxis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hematoma volume | within the 14 days after two weeks of intervention | — |
| National Institutes of Health Stroke Scale (NIHSS) scores | within the 14 days after two weeks of intervention | were measured for stroke severity |
| Barthel index | within the 14 days after two weeks of intervention | were measured for quality of life |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse events | 14 days | such as rash, allergic shock |
Outcome results
None listed